Furmonertinib is a third-generation targeted therapy drug targeting epidermal growth factor receptor (EGFR) gene mutations, primarily indicated for the treatment of non-small cell lung cancer (NSCLC). Its common side effects include skin reactions (such as rash and pruritus), diarrhea, oral ulcers, and abnormal liver function, most of which are mild and manageable; rare but severe side effects may involve interstitial lung disease or cardiotoxicity, requiring immediate medical attention. Patients must strictly follow the doctor's instructions for medication use and regularly monitor physical indicators.
Common Side Effects and Management
Skin Reactions
Approximately 30% to 50% of patients may develop a rash or dry skin, which usually occurs in the initial stage of treatment. It is recommended to keep the skin clean, avoid sun exposure, and use mild moisturizers or topical medications prescribed by a doctor when necessary.
Diarrhea
The incidence rate ranges from 20% to 40%, and most cases are mild. Dietary adjustments (such as avoiding high-fat foods) and fluid supplementation are advised; antidiarrheal medications may be used under medical supervision if the condition persists and worsens.
Oral Ulcers
Occurring in about 10% to 20% of patients, these can be relieved by rinsing the mouth with normal saline or using mucosal protectants recommended by a doctor.
Abnormal Liver Function
Manifested as elevated transaminase levels, regular re-examination of liver function indicators is required, and dose adjustment or temporary drug discontinuation may be necessary as directed by a physician.
Severe Side Effects Requiring Vigilance
Interstitial Lung Disease (Incidence < 1%)
In the event of sudden dyspnea, aggravated cough, or fever, the drug must be discontinued immediately and medical attention sought promptly; hormonal therapy may be required for treatment.
Cardiotoxicity
Including QT interval prolongation or abnormal heart rate, regular electrocardiogram monitoring is necessary during medication, especially for patients with a history of heart disease.
Severe Liver Injury
Rare but potentially life-threatening, immediate drug discontinuation and medical consultation are required if jaundice, abdominal pain, or dark urine occurs.
Other Precautions
Mild symptoms such as fatigue and loss of appetite generally do not require special treatment, but communication with a doctor is necessary if they persist and affect daily life.
Live vaccination should be avoided during medication, and other treating physicians should be informed of the ongoing targeted therapy.
Pregnant women, breastfeeding women, and patients with impaired liver and kidney function need a careful risk assessment.
All treatments must be administered under the guidance of a qualified physician. Do not adjust the dosage or discontinue the drug without authorization. If any suspected side effect symptoms occur, contact the attending physician promptly and complete relevant examinations.
